Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe something positive coming next week…
You should read the investor presentation for May 2021 on their website. Good detail about their financing and development plan. My take away is that this has considerable chance to be really big, but it’s going to take time and dilutive financing. Scoop up those cheapies while you can, you’ll be glad you did :).
http://respirerx.com/presentations/
I bought the dip too ;)
Lol they gave me a partial and then dumped lower and never gave me a complete fill. ETRF is retail someone wants out
Scared money being transferred to the patient, time will tell I suppose
I'm seeing basically the same action across most of the OTC still. Sucks.
Manipulation and/or triggered stops.
Already back up to 4.
The sky is falling.
The sky is falling.
lol. NOT.
Thanks for the .029X’s!!
RSPI
RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury
BY GlobeNewswire
— 9:15 AM ET 05/12/2021
Glen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI ) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Drs. Sabhya Rana, Michael Sunshine and David Fuller presented a poster entitled “Low Dose Ampakine Stimulates Diaphragm Activity and Increases Tidal Volume Following Cervical Spinal Cord Injury in Non-anesthetized Freely Behaving Rats” at the Annual Experimental Biology Conference, which was conducted online this year April 27-30.
The Company has been working with Dr. Fuller at the University of Florida who has funding from NIH, to evaluate the use of our AMPAkines for the treatment of compromised motor function in spinal cord injury (“SCI”). In prior studies, the Fuller Laboratory has shown that acute treatment with AMPAkines CX717 and CX1739 can increase inspiratory phrenic motor output in rat models of incomplete cervical spinal cord injury (SCI), when studied under anesthesia in a surgical setting. AMPAkines were observed to increase motor nerve activity under baseline conditions as well when given in conjunction with acute intermittent hypoxia, a treatment known to stimulate synaptic plasticity.
The results presented at the conference were conducted in awake, freely moving rats, a condition analogous to that experienced by SCI patients in the real world. At 4 and 14 days following C2 cervical spinal hemi-section injury, rats were given single, low dose (5 mg/kg) intravenous injections of CX717, CX1739 or vehicle. At 4-days following injury, both AMPAkines increased diaphragm motor nerve activity (EMG) ipsilateral to the injured side during both the baseline breathing and the acute respiratory challenge. At 14-days following injury, both AMPAkines produced sustained increases in ipsilateral diaphragm EMG output and increased output during respiratory challenge.
According to Dr. Fuller, “Cervical SCI results in respiratory compromise which is a leading cause of mortality and morbidity. These animal models of motor nerve function following SCI support proof of concept for a new treatment paradigm using AMPAkines to improve motor functions in patients with SCI.”
Dr. Arnold Lippa, Chief Scientific Officer of the Company said that, “We are continuing our collaborative preclinical research with Dr. Fuller to determine whether other forms of motor activity might be improved. At the same time, we are planning a clinical trial program focused on developing AMPAkines for the restoration of certain motor functions in patients with SCI. The Company is working with researchers at highly regarded clinical sites to finalize a Phase 2 clinical trial protocol, which we intend to submit to the FDA.”
Tim Jones, CEO and President of the Company said that “The ongoing collaboration between RespireRx and the University of Florida has generated potentially groundbreaking data in the treatment of spinal cord injury. We are very excited by the role that our AMPAkine product candidates may play in further progressing much needed treatments for SCI.”
A copy of the poster presented at the Annual Experimental Biology Conference may be viewed on our website at www.respirerx.com/presentations/
And the arm wrestling with CDEL is laughable. They’ve created opportunity with their blatant games.
RSPI
That’s not how valuation works. A financing arrangement like the once detailed in the PR will definitely favor the lender but the .02 conversion rate isn’t a valuation determinant of the company. Basically this got them another year of operating expenses to further the various Phase studies.
Ideally, they receive FDA approval along the way for one of their treatments and are bought out by a major pharmaceutical company. The longer it takes the more deals like this will be done thereby increasing the O/S which in turn decreases shareholder value. For investors its like a race against the clock and the major risk is how high will the O/S get before FDA approval and profitable viability can be shown.
I’m confident in my DD and holdings. The pps could stagnate in the .04-.05 range for months, could suddenly spike to a $1.00+ with news of positive results and FDA approval (especially if the O/S stays in the low 100 millions) or it could take more years and more dilution and the pps drifts back down to the sub .01 range...Only time will tell. My money is on the middle scenario.
I wish, but according to this PR yesterday, they value it at .02.
https://www.marketscreener.com/quote/stock/RESPIRERX-PHARMACEUTICALS-111313448/news/RESPIRERX-PHARMACEUTICALS-INC-nbsp-Entry-into-a-Material-Definitive-Agreement-Creation-of-a-Dire-33145634/
Very informative PR. Looks like $RSPI is actively researching, achieving goals and gaining more recognition. This is exactly what I wanted to hear.
Yes she is ready for a run , congrats to those in under .04 , big money coming
Ok, NOW she's ready!
Nice close...someone scooped up 100K shares
Newest press release > $3M company
https://twitter.com/respirerxpharma/status/1385247410562154499?s=21
Financial alignment is a huge piece of this puzzle. A personal favorite of mine.
Timing. Timing. Timing.
Apu_85, also don’t forget that E*TRADE/Morgan Stanley street name counts as (1) TD/Ameritrade (2) Charles Schwab (3) so that 95 stockholder number is WAAAAY off-base here. We all know it. But the reverse split wiped out big chunks from those brokerages.
RSPI
The good news is that nobody is more impacted by dilution than current management so we are aligned there.
It's crazy there are only 95 common stockholders...
Here is info on their financing. They referenced $10-$14M for Sleep Apnea Phase 3 trial.
Financing our Platforms
We anticipate filing a Form 1-A with the SEC, which if qualified would enable the Company to engage in a Regulation A
offering (Reg A Offering). We provide no assurance that we will file a Form 1-A, or if filed that the Reg A Offering would be
qualified, or if qualified, would result in a financing on terms as to price per share or other securities offered, amount of funds raised or
other terms acceptable to the Company or at all. Our major challenge has been to raise substantial equity or equity-linked financing to
support research and development plans for our cannabinoid and neuromodulator platforms, while minimizing the dilutive effect to
pre-existing stockholders. At present, we believe that we are hindered primarily by our public corporate structure, our OTCQB listing,
and low market capitalization as a result of our low stock price. For this reason, the Company has effected an internal restructuring plan
through which our two drug platforms have been reorganized into separate businesses units, and may, in the future, be spun out into
subsidiaries.
We believe that by creating one or more subsidiaries to further the aims of Project ResolutionRx and Project EndeavourRx, it
may be possible, through separate finance channels, to optimize the asset values of each.
For a more detailed discussion of our Cannabinoid and Neuromodulator programs, see subsections I and II under Item 1 –
Business above.
Right, we are at about 80 million shares out now.
And depending on the share structure at the time the breakout could be extremely explosive! If major news comes out with the share structure being in the low 100 million range (100-150 million) it would send the pps to $$$. If it’s in the 250-500 million range it’s still good but not as good.
We all know some dilution is coming let’s just hope great news precedes and offsets any real funding dilution.
At least they keep current. Just a matter of time, and we get a breakout, IMO.
We’ll see how the market reacts to the 10K...would be nice if they put out a forward looking PR tomorrow.
Just waiting on the financials and news on Phase 3 trials
Nevermind, closed for Good Friday. I thought it might be for something interesting.
Anybody have any guesses why trading has been halted on this today???
Okay, we're doing this again. I'll check back in another couple weeks, see if this nonsense is over with.
From their updated OTCQB certification, which was from 02/05/2021, it shows 75646039.... I think it's just being manipulated right now. Positive news should set it off. I've been adding these last few days.
Yeah love this chart too. Do we know if OS is still close to 80M? I don't see any diluting MM here, just same MM manipulation that's happening across entire OTC here.
LOL. Yeah they're making a market alright. They're making it the most manipulated market in history.
Stop losses with an OTC will get taken out on slow days. The MMs are just looking for shares and activity to “make a market”...
I like the way this one is setting up. The chart is looking pretty.
Chart here is great too. Just waiting for the OTC market to return to normal after 2 months of blood.
I agree. This one will come out of the blue.
The 13G should help, buy/add/hold is still my consensus for now.
Some bio on Dr. Safranek from Nebraska. His buying might explain the recent surge in volume. He has about a $200,000 investment here now.
https://doctor.webmd.com/doctor/s81017019/john-safranek-conditions-procedures
LOL fair point, but just thought interesting that a random MD bought in.
You can buy 5% of $RSPI for < $200K.
Interesting, let’s see what happens next.
New 13G filed today - Doctor John Safranek for over 5%?? Doesn’t look to be associated with the company
i will be buying more here next week
.052 area maybe rock bottom, time will tell I guess
Would add in low .06’s if I could but fully loaded for now.
Some nice news would send this
Followers
|
352
|
Posters
|
|
Posts (Today)
|
50
|
Posts (Total)
|
49342
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody powerbattles fly_fisherman archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |